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ABSTRACT
The first part of this dissertation concerns statistical analysis of in vitro assay data
derived from tumor cells. An in vitro assay, ChemoFx R©, has been developed to predict
patient’s clinical chemosensitivity. We explore statistical methods that can more efficient-
ly use the assay data and improve the prediction of clinical outcome. In typical analysis
of assay dose-response data, summary statistics such as the area under the dose-response
curve, and concentration at half inhibition (IC50) are estimated from the assay data, then
these statistics are dichotomized to predict the clinical outcome as sensitive or resistant.
Considering the rigidness of the traditional models for dose-response curve fitting and the
information loss in use of cell counts in the control wells, here we propose a mixture of expo-
nential functions for fitting the dose-response curve and a branching process-based method
to summarize the control well data. Simulation studies and analysis of clinical trial data
show that the proposed method improves the prediction performance over some traditional
methods. The second part concerns statistical analysis of regression data with nonresponses.
Missing data are prevalent in clinical trials and public health studies. The often unknown
mechanism for the missing data process may actually be associated with the underlying
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values. Standard statistical methods, including likelihood-based methods and weighted es-
timating equations, require a model for the missing-data mechanism and incorporate it in
the estimation and inference. Misspecification of the missing-data model often causes bi-
ased estimates and wrongful conclusions. The expectation-maximization (EM) algorithm is
an iterative algorithm that is often used to find the maximum likelihood estimate for the
likelihood-based methods. In the E-steps, given a current estimate and the missing-data
mechanism, the conditional expectations of the sufficient statistics are calculated. Under the
premise that the current estimate is consistent, we find that those conditional expectations
could be approximated from the empirical data without the need for assuming or modeling
the missing-data mechanism. Subsequently, we propose a modified EM algorithm regardless
of the potential missing-data mechanism. Simulation studies show that the parameter es-
timates have negligible bias and are more efficient than the initial estimates obtained from
external data.
Keywords: Dose-response curve; Curve fitting; Branching process; Analysis of missing data;
Non-ignorable nonresponse; EM algorithm.
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1.0 INTRODUCTION
1.1 CLASSIFICATION OF ASSAY DOSE-RESPONSE DATA
ChemoFx R© assay is an experimental tool that uses a patient’s tumor chemoresponse in vitro
to predict the patient’s clinical response. This technology has been used in clinical practice
for some time to help physicians in treatment decision [Ochs et al., 2005.].
In vitro assays, e.g. ChemoFx, are usually conducted in a dose-response fashion, with
tumor cells exposed to a series of a monotonically increasing dosages of the chemotherapeu-
tic agent of interest[Brower et al., 2008]. The goal is to use the in vitro assay results to
predict patients’ clinical outcome such as clinical/pathological response, disease progression
or survival. Typically, the analysis of assay data is involved with two stages: first, the dose-
response data is reduced to some summary statistics, such as area under the dose-response
curve (AUC), the drug concentration that achieves a target effect (e.g. IC50); these sum-
mary statistics are then used to predict the clinical outcome using some statistical methods
(e.g., logistic regression model or Cox model).
The relationship between the in vitro and in vivo systems is usually complex. Traditional
methods such as AUC (usually based on non-parametric approach, using trapezoidal rule)
and IC50 (usually based on 4-parameter logistic regression (4PL)) sometimes can not well
differentiate sensitive and resistant curves. Four parameter logistic model (4PL) -derived
IC50 shows some relative advantage comparing with the summation of the last three re-
sponses on the dose-response curve [Huang and Pang, 2008], but the 4PL parametric curve
fitting requires the compliance of the data. For instance, the observed data have to show
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a sigmoidal shape as well as the lower and higher plateaus. In reality, though, the data do
not always satisfy these requirements. Therefore, we propose a five-parameter mixture of
exponential functional form (5ME) which is more flexible in modeling dose-response curves.
Similar to the 4PL method, the fitted parameters of 5ME have explicit biological meanings
and can be used as predictors in the second stage of patient classification.
Typically, the dose-response curve fitting (e.g. 4PL) for the purpose to estimate IC50 or
the AUC analysis is based on the baseline-standardized data, where the data at each point
(e.g. number of survival cell counts at each drug concentration) is standardized by the data
at the baseline (e.g. cell count when the sample is not treated by drugs) so that the model is
fitted on the relative activity. Obviously, the baseline information itself is not fully used in
the curve fitting, and it is lost if only AUC or IC50 is used in the downstream analysis. Even
if the baseline information is used, oftentimes people only consider the mean but ignore the
variance of the cell counts from the different control wells. It has been proposed that the
growth rate of tumor cells (without exposing to drug) may be reflective of some intrinsic
biologic behaviors and therefore affects the patient prognosis. We propose a branching pro-
cess method for possibly better utilizing the baseline data information (dose-0 cell counts).
Here we simply assumed a cell splitting process following a Bernoulli distribution, in which
the estimated Bernoulli probability that quantify the cell characters is then used for patient
classification.
The performance of 5ME methods is compared with IC50 and AUC methods through
simulation studies and the prediction of clinical outcome was evaluated based on the data
from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-40 trial and Preci-
sion Therapeutics Inc. (PTI) -206 trial.
2
1.2 STATISTICAL ANALYSIS OF MISSING DATA
There are many methods developed in the past few decades for statistical analysis of data
with non-response. Based on how the joint distribution of the complete data and nonresponse
indicator is factorized, these methods classified into selection models and pattern-mixture
models. Selection models factor the likelihood into the distribution of the underlying com-
plete data and the conditional distribution of the missing data indicator given the underlying
complete data. Pattern-mixture models stratify the data by the patterns of missing values
and model the distribution of data within each stratum.
For selection models, usually standard statistical methods such as maximum likelihood,
weighted GEE and Bayesian methods require a correct model for the missing-data mecha-
nism. Misspecification of the missing-data model often causes biased estimates and wrong
conclusions. However, in practice, investigators do not have concretes knowledge about
missing-data mechanism. With the selection model framework here we proposed a modified
EM algorithm in maximum likelihood methods, assuming the distinction between the pa-
rameters for the complete data distribution and those for the missing data mechanism.
The expectation-maximization (EM) algorithm is an iterative algorithm that is often
used to find the maximum likelihood estimate for the likelihood-based methods. In the E-
steps, given a current estimate and a model for the missing-data mechanism, the conditional
expectations of the sufficient statistics are calculated. Under the premise that the current
estimate is consistent, we found that those conditional expectations could be approximated
from the empirical data without the need for modeling the missing-data mechanism.
Therefore we can achieve inference of data distribution parameters using this modified
EM algorithm regardless of the potential missing-data mechanism. The consistent initial
value can be either obtained from an external complete dataset or complete recall on a sub-
set.
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The proposed modified EM algorithm method was illustrated in simulation studies and
an analysis of quality of life data from a clinical trial. The simulation studies showed that
the parameter estimates had negligible bias and were more efficient than the initial values
obtained from external data.
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2.0 STATISTICAL METHODS FOR PATIENT CHEMOSENSITIVITY
PREDICTION BASED ON IN VITRO DOSE-RESPONSE DATA
2.1 OVERVIEW OF ANALYSIS OF ASSAY DOSE-RESPONSE DATA
2.1.1 Cancer biomarkers and ChemoFx R© assay
Based on the definition provided by the National Cancer Institute (NCI) 1:
Tumor is an abnormal mass of tissue that results when cells divide more than they should
or do not die when they should.
A tumor marker is a substance found in tissue, blood, or other body fluids that may be a
sign of cancer or certain benign (noncancerous) conditions. Most tumor markers are made
by both normal cells and cancer cells, but they are made in larger amounts by cancer cells. A
tumor marker may help to diagnose cancer, plan treatment, or find out how well treatment
is working or if cancer has come back.
The classification of biomarkers does not have a general rule. From different aspect of
knowledge [Mishra and Verma, 2010], we may have many choices of biomarker classification
methods. We can classify biomarkers into prediction biomarkers, detection biomarkers, diag-
nosis biomarkers and prognosis biomarkers based on the disease state in which the biomarkers
are utilized, or into DNA biomarkers, RNA biomarkers, protein biomarkers and carbohydrate
biomarkers based on the biomolecules that have been used. Also for cancer biomarkers, it is
1http://www.cancer.gov/dictionary
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natural that we classify them by organ sites. For example, human fibroblast growth factor
receptor 2 (HER2) is one of the recommended biomarkers for treatment planning for breast
cancer patients. It is a predictive biomarker for breast cancer, and is usually measured by
mRNA expression, so it is also an RNA biomarker. Other markers such as viral markers and
imaging markers are also broadly used in cancer diagnosis and prognosis.[Yu et al., 1990,
Abraham et al., 1996]
In vitro assay can be used as a predictive biomarker to assist clinicians in selecting the
most suitable chemotherapeutic treatment for each cancer patient. Developed by Precision
Therapeutics Inc. (PTI) 2, the ChemoFx R© assay is an ex vivo assay that measures the cancer
patient’s tumor responses to multiple chemotherapeutic agents simultaneously. The ratio-
nale of the ChemoFx R© assay is based on the adherent character of monolayer-growing cells
in culture that the cells die when they detach from the culture surface [Brower et al., 2008].
The anti-cancer agent’s effect can be measured based on the survival fraction of tumor cells
after treated for a fixed time - 72 hours. The assay results for different agents are compared
within each patient and the most sensitive one(s) can be selected foe individualized therapy.
The typical design of a ChemoFx R© assay plate is shown in Figure 1. The assay plate
consists of 384 (16 × 24) wells. In this assay experiment, the wells at the margin are not
used to avoid edge effect. An assay is defined as a patient’s cell treated by the standard of
care (SOC) treatment options. Therefore, for each patient, the assay is consisted of a panel
of treatments. Every two assays took three lines of wells with increasing dose from left to
right. For example, the wells in line B-D, column 02-23 are used by two assays (one in gray
color and one in white color), the dose or drug concentration is indexed numerically from
0-10. Note that for each assay, the same dose is applied repeatedly in three wells. As such,
for each patient, there are three wells of cell counts for a drug concentration , except that
for dose 0 there are 3 × n of replicates, where n is the number of SOC treatment options
applied to the cells.
2http://www.precisiontherapeutics.com/
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At time 0, each well is placed with the same amount of cells, variation can occur due to
technical variability, then different concentrations of chemo-drugs are applied to each well.
After 72 hours of either free or prohibited growth, the cell counts in the wells are recorded.
Then the mean of cell counts in the untreated wells (dose-0) for each patient is used as the
baseline for that patient. The cell survival proportion (dose-response) from dose 1-10 for the
patient is then derived by dividing each data point (mean cell counts at each concentration)
by the baseline.
Figure 1: Layout of a typical 384 (16× 24) - well plate in the ChemoFx R© Assay
In actual practice, the tumor cells are acquired from fresh tissues collected at surgery.
The cells are then cultured in the lab as mono-layers for several weeks. After the cell quality
and quantity meet pre-defined standards, they will be transferred from flasks to the plates
for the assay [Ochs et al., 2005.] to assess their chemo-sensitivity.
2.1.2 Review of metrics for quantifying dose-response assay
A dose-response curve (DRC) is an X-Y plot relating assay response (e.g., cell survival rate
for ChemoFx) and corresponding dose [Huang and Pang, 2008]. Figure 2 provides an exam-
ple of dose-response curves from ChemoFx assay [Suchy et al., 2011].
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Figure 2: Dose response curves (DRCs) of the breast specimens treated with sunitinib.
Responsive (R) specimens are denoted with a solid black line 3/39 (7.6%), intermediate
responsive (IR) specimens are delineated with a dashed black line 8/39 (20.5%) and non-
responsive (NR) specimens are indicated by a gray line 28/39 (71.7%)
For the baseline adjustment of the DRCs, the control well mean (CWM) for a patient is
defined as the mean cell counts in the untreated wells:
CWM i =
1
M
M∑
m=1
X0i,m (2.1)
Where M represents number of dose-0 wells for each patient, and X0i,m represents the cell
counts from each dose-0 well. Since nine drugs are usually tested on one plate, with each
measurements repeated three times, the maximum of M is 27 based on the assay design.
But in practice M varies because of the possible failure of assays or insufficient cells for all
of the treatment.
Dose response (DR) at dose k is then defined as the cell survival fraction using the mean
of cell counts from different wells at dose-k divided by the CWM for a patient i:
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DRi,j,k =
Y ki
CWMi
, k = 1, 2, . . . , 10. (2.2)
where mean cell counts at dose-k is the average of the three reps, as Y ki =
1
3
∑3
p=1 Y
k
i,p.
A DRC describes the change of cell-killing percentages with the increasing drug concen-
trations for each treatment option. The goal is to assess the tumor cells in vitro sensitivity
to each of the clinical treatment options, this is then used to predict the patient’s clinical
response to the treatments and thus help physicians in making treatment decisions.
In practice, investigators usually use a two-stage approach for classification based on
DRCs [Huang and Pang, 2008]. In the first stage, summary statistics are extracted from
each DRC, with choices of methods including half-maximal inhibitory concentration (IC50),
area under dose-response curves (AUC). In the second stage, the summary statistics extract-
ed from the first stage and other baseline variables are used to predict clinical response.
The half-maximal inhibitory concentration (IC50) and area under does response curves
(AUC) are both common choices of traditional methods for extracting summary statistics
from the dose-response data from assay experiments [Huang and Pang, 2008].
Absolute IC50 is defined as the concentration which generates half of the maximal effect
- mid-point between the max effect and zero [Cheng, 2002]. Relative IC50 is similar to
absolute IC50 except that the maximal effect is adjusted by a baseline (minimal effect)- the
mid-point between the max effect and the min effect. The difference between absolute IC50
and relative IC50 can be demonstrated in Figure 3.
In in vitro dose-response assays, IC50 is the most widely used metric to analyze DRCs,
and it is usually estimated based on a parametric approach. For a given drug, assays with
a larger IC50 suggests that the tumor cells are more resistant to the drug.
The area under the DRC, a.k.a. AUC, is another common method for quantifying dose-
response curves and used for curve comparisons [Mi et al., 2008]. It is defined as the sum of
9
Figure 3: Definition of IC50, relative IC50 and AUC on a DRC.
DR at dose from 1-10:
AUC =
10∑
k=1
DRk (2.3)
AUC method is used to quantify the relative height of the DRCs. When comparing the
DRCs of two patients treated with the same drug, the lower DRC suggests that the tumor
cells of that patient is be more sensitive to the drug. The convenience of interpretation of
AUC in predicting clinical response is a great advantage of the method.
Truncated or partial AUC is a modification of AUC method. The motivation for this
approach is that during the model training it is found that not all of the concentrations
are informative (correlated with) the clinical outcome. AUC7, for example, computes the
AUC using DRs at dose from 1-7, considering that the growth of tumor cells under high
concentration (dose 8-10) may not be distinguished for different drugs.
AUC and IC50 both reduce the dimension of the DR data from 10 to one (assuming
that the triplicate measurements at each concentration are averaged first). This dimension
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reduction may simplify the prediction model in the second stage. AUC and IC50 methods
also have clear and intuitive interpretation.
When the CWMs change, IC50s will stay the same, because the calculation of IC50 de-
pends on the relative change of dose-response. AUCs can be affected in that situation, and
thus prediction of clinical response is also impacted. The information about the free growth
of tumor cells itself is indicative of how aggressive the tumor cells are, and it should be in
the prediction model.
As usual, there could be loss of information in the dimension reduction process when only
IC50 and AUC are used to summarize the dose-response data. For example, as shown in
Figure 4, two dose-response curves have the same AUCs and IC50s, but the chemo-sensitive
kinetics might be totally different, because part of the information on the cell killing mech-
anism is not captured by AUC or IC50.
To address the above concern, the DRCs should be fitted with a function that is required
to not only reduce the dimension of the data, but also describe the curve kinetics. Four-
parameter logistic function (4PL) is widely used for fitting DRCs in industry. The 4PL
function is defined as in [Huang and Pang, 2008]:
y = β2 +
β1 − β2
1 + (β4
x
)β3
(2.4)
Here, β2 denotes upper plateau, β1 denotes lower plateau, β3 denotes slope/speed of response
to dosage change, and β4 denotes IC50.
An alternative version of 4PL function could be used[Ritz and Streibig, 2005]
y = β2 +
β1 − β2
1 + eβ3(β4−x)
(2.5)
In this form of four parameter logistic model, β1,β2 and β3 will be similar to that in formula
(2.4); β4 and x here will be similar to log(β4) and log(x) in formula (2.4), considering the
fact that eβ3β4 should be very large. In assay dose-response data analysis, we usually use
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Figure 4: Four-parameter logistic function (4PL). 4PL with (β1, β2, β2, β4) = (1, 0.2, 1, 5) is
corresponding to the red curve, 4PL with (β1, β2, β2, β4) = (1, 0.2, 3, 5) is corresponding to
the green curve.
(2.5) taking into account that the dose k from 1-10 represent the drug concentrations expo- 
nentially increasing with base 10.
In Figure 4, the 4PL function of index dosage x from 0 to 10 are plotted under two setups 
of parameters. β4 = 5 was set for both curves, this means that both curves have IC50 = 5 (i.e., 
the dose x where derivative of f(x) reaches maximum). By setting β1 = 1 and β2 = 0.2, both 
curves start from cell survival proportion 1 and end with 0.2. By setting β3 = 3 (red) or 5 
(green), they have different slopes at dose x = 5.
As interpreted with the plot of DRCs, each parameter in the 4PL function has explicit 
meaning in the interpretation. Once the DRC is fitted with 4PL function, the parameters may 
be used as inputs in the prediction of patient's chemotherapy sensitivity.
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4PL model reduces the dimension of the DR data from 10 to 4, it preserves more in- 
formation regarding dose-response mechanism than AUC or IC50 alone. Generally, when the 
drug concentrations are well designed and the noise level is well controlled (so that the data 
complies with the 4PL model fitting assumptions), the 4PL model performs better than using 
only the highest 3 dose-responses [Huang and Pang, 2008].
2.2 THE PROPOSED METHODS FOR CLASSIFICATION BASED ON
DOSE-RESPONSE DATA
2.2.1 Five-parameter mixture of exponential function (5ME) method
The 4PL model is a useful functional form that describes DRC’s with flat top and bottom
(low and high dosage). However, in reality such low/high-dose plateaus do not always exist,
it is then a mathematical challenge to estimate the IC50 if the DRC does not comply with
the model fitting assumptions. Illustrated in Figure 5, specimens from National Surgical
Adjuvant Breast and Bowel Project (NSABP) B-40 trial with patients treated by T+AC
without Bev. In ChemoFx assay experiment, the DRCs using doxorubicin (drug A) usu-
ally does not have flat beginning and ending. Biologically, such two-phased exponentially
decreasing trend in DRCs is not uncommon and quite often the cause is unknown; in this
case, it could be caused by the mixture of tumor cells and fibroblast cells in the specimens.
Therefore, another functional form is needed to fit this type of unusual DRCs with steep ends.
Here we propose a five-parameter mixture of exponential function (5ME) method for dose
response curve fitting. The 5ME function consists of two different exponential decreasing
components:
f(x) = ρ{1 + a[1− ebx]}+ (1− ρ){c+ (1− c)e−dx}, x = 0, 1, . . . , 10. (2.6)
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Figure 5: Mean of DRCs of the breast specimens treated with doxorubicin (A). Specimens
from pathological complete response (pCR) groups are corresponding to the red line, speci-
mens from non-pCR groups are corresponding to the black line.
where x denotes the dosage, (a, b, c, d) are parameters describing the dose-response mech-
anism of the DRC: Under lower dosage, we assume that the DRCs start with a fast drop
and slow down as f(x) = e−dx; Under higher dosage, we assume that the DRCs start with
a slow drop and accelerate the decreasing as f(x) = 1 − ebx. ρ denotes a weight parame-
ter for how much proportion of the DRC is shared by each component of exponential function.
In Figure 6, we present plots of 5ME functions under two setups of parameters. Param-
eters (a,b,c,d) are set as the same for both curves, which means that the 2 components of
exponentially decreasing function are exactly the same for both curves. We set the weight
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Figure 6: Five-parameter mixture of exponential function (5ME). 5ME with (a, b, c, d, ρ) =
(0.01, 0.4, 0.05, 0.5, 0.8) is corresponding to the red curve, 5ME with (a, b, c, d, ρ) =
(0.01, 0.4, 0.05, 0.5, 0.2) is corresponding to the green curve.
parameter to be ρ = 0.8 or 0.2, such that the two curves have different proportions of
the two exponential functions. The red curve consists of 80% of f(x) = 1− ebx and 20% of
f(x) = e−dx, whereas the blue curve consists of 20% of f(x) = 1−ebx and 80% of f(x) = e−dx.
Similar as 4PL method, after the nonlinear curve fitting, the estimated parameters can
be used as inputs of the prediction model for patients’ chemotherapy sensitivity.
Compared with non-parametric methods, parametric curve fitting methods such as 4PL
and 5ME focus more on the dose-response mechanism when extracting summary statistics
from DRCs. If the mechanisms agree with the model assumptions, parametric curve fit-
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ting should outperform the non-parametric methods. On the other hand, non-parametric
models such as AUC and non-parametric IC50 are less sensitive to the violation of the model .
2.2.2 Branching process using dose-0 cell counts data
As discussed earlier, the sample size of dose-0 cell counts in ChemoFx assays usually varies
from 6 (2 drugs) to 27 (9 drugs). The mean of the dose-0 cell counts, CWM, is used for
the standardization of DRCs. The dose-0 cell counts data are usually not used in predict-
ing patients’ chemotherapy sensitivity. Even if the baseline information is used, oftentimes
people only consider the mean but ignore the variance. Simply adding mean and variance
of dose-0 cell counts may improve the prediction of patient chemo-sensitivity, but extracting
cell growth characteristics from the dose-0 cell counts data could benefit us more in predic-
tion and model interpretation. Here we propose a branching process method for extracting
information on the uninhibited growth of tumor cells from dose-0 cell counts data. By setting
up a proper stochastic process model for cell growth in an assay, we can compute patient
specific characters such as initial cell count in the well, cell division probability, and the
number of cell cycles with a fixed time window.
A branching process models the reproduction of particles such as cell proliferation. A
branching process assumes each particle follows the same probability/rule to produce off-
spring, and there is no interaction between any particles [Lange, 2010]. Time is measured
discretely as generations in a branching process. Here we assume a cell division process
following a Bernoulli distribution.
At time zero of ChemoFx assay, tumor cells are placed in assay plates and are allowed to
grow with or without inhibition for 72 hours. The initial cell counts in wells are unknown.
The assay protocol requires that 320 cells are placed in each well, but this number varies
due to technical variability. Since a typical cell cycle takes 24 hours, we assume that all cells
have experienced three cell cycles. We denote:
16
Figure 7: Branching Process: free growth and drug effect
W0 (TBD): the number of cells initially placed in a well at time zero;
W 0t (measured): the number of cells in the well 72 hours after time zero, no treatment
was applied;
W kt (measured): the number of cells in the well 72 hours after time zero, treatment of
dose-k was applied;
p (TBD): the probability of division in each cell cycle;
n = 3: the number of cell cycles experienced in time duration [0,t], here t = 72 hours.
For each patient, the original assay cell counts data are composed of, (W 0t , W
k
t ), mea-
sured in triplicates, for each treatment. Usually W 0t has more than 20 replicates and W
k
t
has 3 replicates for each k. We are interested in the patient specific parameters (W0, p) that
describes the free growth character of patients’ tumor cells. For a given patient, W0 reflects
how healthy the tumor cells are because the true starting number of cells for each patient
depends on the surviving proportion of cells when they are plated; p reflects how aggressively
the tumor cells grow.
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As shown in Figure 7, for cell growth without inhibition, the branching process is as-
sumed to follow a Bernoulli distribution with probability of division p . The probability of
killing q is only applicable to drug-treated wells. Based on the branching process [Lange,
2010], for the free growth starting from one cell, we have:
µ = E(Y 0t ) = (1 + p)
n
σ2 = V ar(Y 0t ) = (1− p)(1 + p)n−1[(1 + p)n − 1]
Starting from W0 cells:
W0 =
W0∑
j=1
Y0j =
W0∑
j=1
1
W 0t =
W0∑
j=1
Y 0tj
Suppose that W0 is a random variable with mean µW and variance σ
2
W , then conditioning
on p and n we have the mean of W 0t :
E[W 0t |p, n] = EW0 [E[
W0∑
j=1
Y 0tj|W0, p, n]]
= E[(W0|p, n)µ]
= µWµ
E[W 0t |p, n] = µW (1 + p)n (2.7)
Similarly we have conditional variance of W 0t :
V ar[W 0t |p, n] = V arW0 [E[
W0∑
j=1
Y 0tj|W0, p, n]] + EW0 [V ar[
W0∑
j=1
Y 0tj|W0, p, n]]
= V ar[(W0|p, n)µ] + E[(W0|p, n)σ2]
= σ2Wµ
2 + µWσ
2
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V ar[W 0t |p, n] = σ2W (1 + p)2n + µW{(1− p)(1 + p)n−1[(1 + p)n − 1]} (2.8)
Note that our data is only consisted of the dose response well counts after-treatment :
{W 01t ,W 02t ,W 03t , . . . ,W 0 Mt } for dose-0 cell counts (M is the number of replication of dose-0
wells) and {W k1t ,W k2t ,W k3t } for dose-k cell counts (k=1,2,. . . ,10). For patient i, we have:
E(W 0t i) = µW i(1 + p0 i)
ni
E(W kt i) = µW i(1 + p0 i(1− 2qk i))ni
Because the variance of W kt i can not be reliably estimated due to the small sample size
(at most three), here we apply the branching process model only to dose-0 cell counts data
to solve for free growth characters (µW , σ
2
W , p) for each patient.
By setting n = 3, here we have three unknown parameters (µW , σ
2
W , p) and two (mean
and variance) equations (2.7)(2.8), therefore we must add assumptions/constraints on (µW ,
σ2W , p and/or n). Here are some tentative choices:
If the variance is assumed to be σ2W for the initial cell counts W0, we may compute the
mean well counts at initial time µiW and cell division probability pi for each patient i.
Alternatively, if a Poisson distribution of W0 can be assumed that W0 i ∼ POI(λi), we
have
E[W 0t i|p, n] = λi(1 + pi)ni
V ar[W 0t i|p, n] = λi(1 + pi)2ni + λi{(1− pi)(1 + pi)ni−1[(1 + pi)ni − 1]}
then we will have cell division probability and initial cell counts (pi, λi) solved for each pa-
tient i.
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Similar to 4PL and 5ME, the parameters derived from modeling dose-0 cell counts data
using branching process have explicit meanings, and they are then used as inputs to the
prediction model for patient clinical response. For example, if we assume Poisson distribu-
tion of W0, we may have (pi, λi) used as inputs in the prediction of patients’ clinical response.
2.3 SIMULATION STUDIES
2.3.1 Comparing 5ME, IC50, and AUC using simulated cell counts data
In this simulation study we generated cell counts data from a mixture of two branching
process to simulate the growth of the mixture of fibroblast cells and tumor cells. In each
simulation we generated data for 300 patients, 100 labeled with pathological complete re-
sponse (PCR) and the remaining 200 labeled with non-PCR. For a patient i, 10 dose-0
cell counts and 3 dose-k (k=1,. . . ,10) cell counts were generated. Initial cell counts W0
were generated from W0 ∼ POI(Z), where Z ∼ N(300, 502), with the ratio of tumor cells
r ∼ UNIF (0.7, 0.9). Fibroblast cell killing probability qF (k) and tumor cell killing proba-
bility qT (k) (q
+
T for pCR group and q
−
T for non-pCR group) follows:
qF (k) = 1− exp{−0.5k}
q+T (k) = 0.4 +
0.5
1 + exp{0.7(7− k)}
q−T (k) =
1
1 + exp{1.2(6.5− k)}
The mean DRC are presented in Figure 8. Here we chose not to generate the dose-
response data following an exact 5ME function (in fact a 4PL+ exponential function form
was used) because 5ME model is expected to be flexible in fitting DRCs and show its ad-
vantage in prediction. After each simulation, with the 300 patients’ dose-0 and dose-k well
counts, CWM for each patient was computed and used to standardize the DRCs, then we
applied the proposed 5ME method and existing methods such as AUC and IC50 to extract
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Figure 8: Mean DRCs of simulated cell counts data.
summary statistics from the DRCs. We separated the inputs into training set and testing
set (ratio as 4:1) and used a logistic model to predict pCR. The process was repeated for
1000 times. Mean and empirical standard deviation of sensitivity, specificity, PPV, NPV,
and prediction accuracy were computed and compared for each method.
The simulation results are shown in Table 1. The NA′s in PPV column for CWM, IC50
and AUC methods are caused by some extreme predictions of pCR by using these methods
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when all patients in testing set are predicted resistant to chemodrugs. Under the given set-
up of parameters, CWM, IC50 and AUC do not differ between two groups. Therefore the
logistic models using CWM, IC50 or AUC did not provide good prediction of chemosensitiv-
ity. The 5ME curve fitting method in this case can transform the data into the parameter
space and tell the difference between the two groups. Although we choose not to use 5ME
function to generate the data , the method still show its advantage. The prediction accura-
cy using 5ME method is significantly better than those using CWM, IC50 and AUC methods.
Table 1: Comparison of 5ME, IC50 and AUC based on
simulated cell counts
Entries sensitivity specificity PPV NPV PA
1 CWM 0.001 0.99 NA 0.667 0.666
Emp.SD 0.01 0.01 NA 0.002 0.004
2 IC50 + CWM 0.007 0.963 NA 0.659 0.644
Emp.SD 0.03 0.05 NA 0.013 0.034
3 AUC + CWM 0.02 0.99 NA 0.67 0.67
Emp.SD 0.04 0.02 NA 0.01 0.02
4 5ME + CWM 0.50 0.89 0.71 0.78 0.76
Emp.SD 0.12 0.06 0.12 0.04 0.05
2.3.2 Comparing 5ME, IC50, and AUC using simulated dose-response curves
In this simulation study, instead of generating the cell counts from mixture of branching pro-
cesses, here we repeatedly (K=1000) simulated the proportion of cell surviving from some
given functions and artificially adding some errors. Here we generated the dose response
curves from a seven-parameter mixture of an exponential function and a logistic function
(7MEL):
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f(k) = ρ · {a + b− a
1 + exp(c(d− k)))} + (1 − ρ) · {A + (1 − A) · exp(−Bk)} +  (2.9)
where  ∼ UNIF (−0.1, 0.1).
As presented in Figure 9, in each simulation we generate dose-response data following
7MEL function as in (2.9), and eight different setups of parameters θ = (a, b, c, d, A,B, ρ) as
θ+1 = (1, 0.2, 3, 5, 0.5, 0.5, 0.4)
θ−1 = (1, 0.2, 1, 5, 0.5, 0.5, 0.4)
θ+2 = (1, 0.2, 3, 4.5, 0.5, 0.15, 0.4)
θ−2 = (1, 0.18, 1, 4.7, 0.4, 0.1, 0.44)
θ+3 = (1, 0.2, 3, 5.6, 0.4, 0.15, 0.3)
θ−3 = (1, 0.3, 1, 6, 0.5, 0.3, 0.44)
θ+4 = (1, 0.1, 3, 8, 0.4, 0.15, 0.3)
θ−4 = (1, 0.2, 1, 8, 0.5, 0.3, 0.44)
Table 2: Comparing 5ME, IC50 and AUC using simulat-
ed dose-response data
Entries sensitivity specificity PPV NPV PA
1 IC50 0.61 0.49 0.56 0.57 0.55
Emp.SD 0.19 0.20 0.05 0.05 0.02
2 AUC 0.71 0.55 0.61 0.65 0.63
Emp.SD 0.06 0.07 0.03 0.05 0.04
3 5ME 0.79 0.56 0.64 0.73 0.67
Emp.SD 0.06 0.06 0.03 0.05 0.03
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(a) 7MEL functions with θ+1 and θ
−
1 (b) 7MEL functions with θ
+
2 and θ
−
2
(c) 7MEL functions with θ+3 and θ
−
3 (d) 7MEL functions with θ
+
4 and θ
−
4
Figure 9: Mean of Simulated DRC following seven-parameter mixture of a 4PL function and
an exponential function (7MEL) functions.
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Among the eight setups of parameters, we use θ+1 , θ
+
2 , θ
+
3 , and θ
+
4 for generating DRCs
for sensitive patients, and θ−1 , θ
−
2 , θ
−
3 , and θ
−
4 for generating DRCs for resistant patients.
We generate 9600 DRCs (1200 for each θ), split them into training set and testing set in a
5:1 ratio, and apply the proposed 5ME methods and traditional methods such as IC50 and
AUC. We repeated the process for K = 1000 times. Mean and empirical standard deviation
of sensitivity, specificity, PPV, NPV, and prediction accuracy were computed and compared
for each method.
Table 2 summarizes the performance of these methods using dose-response data simulat-
ed from 7MEL functions. Here since we set the parameters θ’s in pairs such that the AUC
and IC50 are similar between the sensitive and the resistant groups, the prediction accuracy
is relatively low as we expected. Compared to IC50 and AUC, the proposed 5ME method
shows better performance predicting responses in such a mixture pattern situation.
2.4 APPLICATION TO CLINICAL TRIAL DATA
2.4.1 Analysis of B40 trial data
National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocal B-40 was designed
to determine if adding capecitabine(X) or gemcitabine(G) to neo-adjuvant docetaxel followed
by doxorubicin/cyclophosphamide(T+AC) and if adding bevacizumab(Bev) to chemothera-
py would improve pathologic complete response(pCR) rate of breast cancer patients.
Pathologic complete response(pCR) is defined as no invasive and no in situ residuals in
breast and nodes for breast cancer patients [Minckwitz et al., 2012]. pCR can be associated
with patient disease free survival (DFS) after treatment. For some subgroup of patients,
pCR can be used as a suitable surrogate end point.
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Figure 10: B-40 Schema
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It was learned from another neoadjuvant trial conducted and reported by NSABP, proto-
col B-27, that adding docetaxel(T) after doxorubicin/cyclophosphamide (AC) significantly
increased clinical and pathological response rates for operable breast cancer [Bear et al., 2003,
2006, Fisher et al., 1997]. Recent research showed that bevacizumab(Bev) and capecitabine
(X) / gemcitabine (G) could possibly improve response rate for some metastatic-disease
[Robert et al., 2011, O’ Shaughnessy et al., 2002, Albain et al., 2008]. Therefore NSABP
protocol B-40 trial followed such factorial design that eligible patients were randomly as-
signed to 3 arms T+AC, TX+AC, and TG+AC, then patients in each arm were randomized
to receive Bev or not(see Figure 10).
At the end of B-40 trial, 1186 of the 1206 patients had available pCR data. The con-
clusion from analysis of B-40 clinical data was that addition of X or G did not significantly
improve pCR rate compared with T alone (pCR rate in Arm 2 and 3 was not significantly
higher than that in Arm 1); addition of Bev to chemotherapy significantly increased pCR
rate (pCR rate in Arm B’s was significantly higher than that in Arm A’s)[Bear et al., 2012].
For patients with positive hormone receptor(HR), the effect of adding Bev was significant,
while for patients with negative HR, the effect was minimal.
In B40 trial, the biopsies from breast cancer patients were delivered to ChemoFx R© as-
say lab in Precision Therapeutics Inc. for ex vivo experiments. Tumors cells were cul-
tured for several weeks until they reached the requirements for assays in both quality and
quantity. Then each patient’s cells were placed by robots into wells on plates to receive
all single drugs and combinations of those drugs (11 assays for B40 in total: T,A,C,X,G,
TX,TG,AC,TAC,TXAC,TGAC).
A total of 473 patients in B40 trial had successful ChemoFx assay experiments using
drug A and T, and 223 of them were involved in arm 1A, 2A, 3A (treated without Bev)
and the remaining 250 were involved in arm 1B, 2B, 3B (treated with Bev). Our validation
was only conducted on 223 patients from arm A and using the assay results for drug A
and T. Patients from arm B were not used because Bev had been proved to significantly
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improve pCR rate, which could confound the results. Drug C was also not used for analy-
sis because there is evidence from the lab that the assay results for this drug were not reliable.
(a) Sample DRC by pCR, drug A (b) Sample DRC by pCR, drug T
Figure 11: Sample dose-response curves in assay with drug A or T, grouped by pCR of
patients in NSABP B-40 Arm 1A.
Figure shows some sample individual DRCs in assay with drug A and T for patients from
arm A1 where T+AC was applied. Unfortunately the mean DRC of patients with pCR was
even higher than that of patients without pCR based on assay results of drug A, which was
the opposite of what we expected. The mean DRCs of patients with pCR and non-pCR were
also not separable based on assay results of drug T, adding into the difficulties of predictions.
The DRCs were standardized by the CWMs. For extracting summary statistics, we ap-
plied AUC7, AUC10, IC50, BP and parametric curve fitting (4PL method for assay using
drug T and 5ME for assay using drug A). We fitted drug A and drug T assays with different
models, because drug T showed DRCs with high and low plateaus, while drug A assays
could only be fitted by 5ME model. The summary statistics from drug A assays and drug
T assays are combined and used as inputs for prediction. We applied 5-fold cross-validation
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(a) Mean DRC by pCR, drug A (b) Mean DRC by pCR, drug T
Figure 12: Mean dose-response curves(DRC’s) in assay with drug A or T, grouped by pCR
of patients in NSABP B-40 Arm 1A.
for K = 1000 times using logistic model to predict patient pCR. The prediction accuracy
and corresponding resampling standard error of these methods are summarized in Table 3.
Table 3: Comparison of methods using B40 ChemoFx
assay data
Method NO.pts Prediction Accuracy Resampling SE
1 DRC + CWM 223 0.67 0.09
2 AUC10 + CWM 223 0.71 0.14
3 AUC7 + CWM 223 0.65 0.09
4 IC50 + CWM 223 0.69 0.07
5 4PL/5ME+CWM 222 0.70 0.13
6 4PL/5ME+BP 198 0.68 0.07
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To compare the methods 1-5, with logistic models using different inputs such as dose-
response data, AUC10, AUC7, nonparametric IC50, or 4PL/5ME, IC50 appeared to have
a smaller resampling SE, and a slightly better prediction accuracy. The 4PL/5ME method
showed a higher prediction accuracy, but the resampling SE was also larger. This was proba-
bly caused by the large noise of the dose-response data, and because parametric models have
more parameters, the variation of prediction performance could be more affected compared
to simple model such as non-parametric IC50. AUC10 also showed a large SE in prediction,
this could be caused by the instability of the responses at higher doses.
To compare methods 5 and 6, with 4PL/5ME approach with or without character vari-
ables from branching process in the model, branching process did not provide any improve-
ment in predicting pCR, this method was also unable to achieve a solution of p for 24 patients.
2.4.2 Analysis of PTI-206 ChemoFx R© assay data
To further validate the performance of the proposed branching process (BP) method, herein
we conducted the analysis using PTI-206 assay data. PTI-206 was a study for advanced
ovarian cancer. In the study, patients were enrolled in a pre-defined protocol. Tumor sam-
ples from 54 institutions were submitted for chemo-response testing between 2006 and 2010.
Women with FIGO stage III-IV epithelial ovarian (EOC), fallopian tube (FTC) and peri-
toneal (PPC) cancer treated with carboplatin (C)/ paclitaxel (P)-based chemotherapy fol-
lowing initial cytoreductive surgery were included in the study. Clinical response (CR) was
defined as positive if a patient experienced more than six months from the end of primary
chemotherapy. If recurrence was reported within six months, then the patient had no CR.
262 patients in the PTI-206 trial had successful ChemoFx assay results. After filtering
out missing data, 230 patients remained with clinical response (CR) and Carboplatin assay
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result (Carboplatin is the drug applied to patients in this trial). The goal of this applica-
tion is to compare the BP with traditional baseline adjustment methods in predicting CR.
AUC7 is used for the prediction in these Chemofx assays, considering the instability of assay
responses at high doses.
For each patient, the data to be used includes AUC7, CWM and dose-0 cell counts. To
apply the BP method, we first computed the mean and variance of dose-0 cell count. Then
assuming all cells experiencing three cycles in 72 hours in the assay experiment (n = 3) and
Poisson distribution for initial well counts (W0 ∼ POI(λ)), we used (2.7,2.8) to compute the
initial mean cell counts λ and cell division probability p for each patient.
To predict CR, logistic models are performed with the following inputs: CWM + vari-
ance of dose-0 counts, λ + p, AUC7 + CWM + variance of dose-0 counts, AUC7 + λ +
p. The performance of prediction was compared by receiver operating characteristic (ROC)
analysis. The ROC plots are shown in Figure 2.4.2. The Area under the ROC curve (AU-
ROC) of each method are summarized in Table 4. AUROC for CWM + variance of dose-0
counts model was 0.617, AUROC for λ + p model was 0.628, AUROC for AUC7 + CWM
+ variance of dose-0 counts model was 0.632, AUROC for AUC7 + λ + p model was 0.647.
Table 4: Comparison of methods by AUROC based on
PTI-206 assay data
Predictors AUROC
1 mean and variance of dose-0 cell counts 0.617
2 (λ, p) from BP 0.628
3 AUC7 + mean and variance of dose-0 cell counts 0.632
4 AUC7 + (λ, p) from BP 0.647
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(a) Inputs: CWM + variance of dose-0 counts (b) Inputs: λ + p
(c) Inputs: AUC7 + CWM + variance of dose-0
counts
(d) Inputs: AUC7 + λ + p
Figure 13: Comparison of methods by ROC analysis using PTI-206 assay data
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First, we compared model 1 and model 2 (CWM + variance of dose-0 counts model vs λ
+ p model). The inputs in these two methods were equivalent in information, because that
λ + p was computed from CWM + variance of dose-0 counts by using BP method. In this
comparison, the BP method improved the AUROC by 1.8%.
We then compared model 3 and model 4 (AUC7 + CWM + variance of dose-0 counts
model vs AUC7 + λ + p model). The inputs in these two methods were also equivalent. In
this comparison, the BP method improved the AUROC by 2.4%.
2.5 DISCUSSIONS
Here we proposed a five-parameter mixture of exponential function (5ME) method for dose-
response curve (DRC) fitting and a branching process (BP) method for dose-response baseline
characterization.
The 5ME model is a parametric curve fitting method similar to the four parameter lo-
gistic model (4PL). The difference between these two models is the type of dose-response
curves they describe. The 5ME model can be fitted into DRCs without upper and bottom
plateau, and an improved performance is seen in simulation study by comparing with other
traditional methods such as IC50 and AUC.
When noise is large as that in the B40 assays, the fitting of 5ME function to DRC is not
precise, and the prediction performance using the curve parameters is than ideal.
The BP method is based on the cell division modeling in an in vitro assay. This method
was illustrated in the analysis of PTI-206 assay data. When applying this model, because
the variance of dose-0 cell counts were utilized, it was expected to provide more information
on the character of patient’s tumor cells. Compared to using mean and variance of dose-
0 cell counts, using λ and p from the BP method improved the prediction of clinical response.
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The improvement by the branching process method, relies on the available biological
knowledge of cell division process in assay experiment. Here we simply assumed that the
number of cell cycles was fixed and the probability of cell division followed a Bernoulli prob-
ability. These assumptions can be refined and the prediction should be improved if we have
more understanding of the experiment and the behavior of tumor cells in the assays, such as
the distribution of initial cells in each well and the cell cycle variation.
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3.0 A MODIFIED EM ALGORITHM FOR REGRESSION ANALYSIS OF
DATA WITH NON-IGNORABLE NON-RESPONSE
3.1 OVERVIEW OF ANALYSIS OF MISSING DATA
3.1.1 Missing data in practice
Missing data are prevalent in biomedical studies especially in large clinical trials and longi-
tudinal studies where values of some variables are missing from many subjects. In general,
missing values may occur due to design, loss to follow-up or inability to record [Little and
Rubin, 2002] [Little et al., 2012].
For example, in some case-control studies, the assessment of a bio-marker is too expen-
sive that the investigators can only afford to perform the assay on a subset, or values of
certain exposure variables may not be available from some subjects based on their existing
records. In many longitudinal studies, an outcome variable is repeatedly measured over time
to provide information on its trend overtime in individuals. The values of the outcome vari-
able may be missing during the study because of missed visits or dropouts.
In most statistical software packages, subjects with missing values are deleted automati-
cally and analysis is solely based on the subsets with complete records on involved variables.
Simply applying standard statistical methods using complete cases often leads to biased es-
timates. The bias can be substantial when the proportion of missing values is high or the
missingness does not occur randomly. Missingness in some variables may cause imbalance in
treatment among the complete cases. For example, in a randomized clinical trial, patients
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are randomized into two treatment arms, to balance the two groups for both known and
unknown factors. If patients’ dropout is related with less improvement of the symptoms
than expected, then the comparison between the treatment groups will be biased in favor of
higher rate of dropout.
It is important to distinguish missing-data patterns and missing-data mechanism because
of their implication in appropriate statistical analysis[Little and Rubin, 2002]. Missing-value
indicators, with value at 1 or 0, are often used to indicate the missing status of a variable
for a subject. Then we have a vector for each subject and a matrix of missing indicators for
all subjects. Such missing indicator matrix forms the missing-data pattern. Missing-data
patterns are used to describe which values are observed and which values are missing. For
example, monotone missing data are related with longitudinal dropouts, when all future ob-
servations are missing after the dropout. Non-monotone missing data are more complicated
and require modeling of the dropout mechanism.
Missing-data mechanism is used to describe how missingness is related with the hypo-
thetical complete data, including missing values. Rubin [Rubin, 1976] defined three types
of missing-data mechanisms: missing completely at random (MCAR), missing at random
(MAR) and not missing at random (NMAR). When missingess is not related with the values
of any variables in the study/data, the data are called MCAR. When missingess is related
with the values of observed variables only, the data are called MAR. When missingess is
related with the values of unobserved variables after conditioning on the observed variables,
the data are called NMAR.
For example, in a randomized clinical trial with two treatment arms, suppose that pa-
tients in treatment group will receive IV injection, whereas those in control group will take
pills. If a patient discontinues the treatment because he does not like the flavor of the pills,
the missing mechanism here is MAR. This is because that the group assignment is observed.
If loss of follow-up is caused by heart attack which is only related to real-time blood pres-
sure, then the missing-data mechanism is NMAR. This is because that the values which
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missingness depend on may not be observed. If loss of follow-up is caused by relocation for
job change, the data are in general MCAR.
3.1.2 Statistical methods for analysis of missing data
In the following context, we denote Y = (Y1, . . . , YK) the vector of variables and R =
(R1, . . . , RK) the vector of missing data indicators. Y = (Yobs, Ymis), Yobs and Ymis denote
the observed and missing components of Y. Rk = 0 if Yk is missing; Rk = 1 if Yk is observed.
Missing-data mechanism is generally described via conditional distribution f(R|Y, ψ), where
ψ denotes parameters for the missing-data mechanism model. Based on how the missingness
is related to the hypothetical complete-data vector Y , Rubin classified three missing-data
mechanisms [Rubin, 1976]:
1. MCAR
Data are missing completely at random(MCAR) if the missingness does not depend on
the underlying complete data at all.
f(R|Y ;ψ) = f(R;ψ) for all Y.
2. MAR
Data are missing at random(MAR) if the missingness depends on observed values only.
f(R|Y ;ψ) = f(R|Yobs, ψ) for all Ymis, ψ.
3. NMAR
When missingness still depends on Ymis after conditioning on Yobs, the data are called
not missing at random (NMAR).
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For regression analysis of a data set, missingness could happen in response, covariates,
or both. The impacts of missing values are different for response and covariate, and yield
different analytical methods.
In the following context, we consider regression analysis of data with nonresponse where
the covariates are fully observed and the response variable is subject to missing values.
Suppose the observed data for (X, Y ) are {(x1, y1), (x2, y2), ..., (xn, yn)}, where x′is are ful-
ly observed, and the response variable Y is only observed for the first r subjects, i.e.,
(yr, yr+1, ..., yn) are missing. In practice, we are usually concerned with the following re-
gression models:
[Y |X] ∼ g(y|x; θ)
where g(·|x; θ) is a parametric or semi-parametric model. Here the interest is to make
inference on θ. There are generally two types of methods in missing-data analyses [Ibrahim
et al., 2012]: ad-hoc methods such as complete case analysis and imputations, and stan-
dard statistical methods such as inverse-probability weighted estimating equations (IPWEE),
maximum likelihood, Bayesian / data augmentation methods.
Complete-case analysis is a simple methods that applies on the complete cases. In
complete-case analysis, the statistical inference on θ is based on the complete cases {(x1, y1),
(x2, y2), ..., (xr, yr)}. Complete-case analysis is based on a well-defined subset and simple to
perform. However, it does not use information collected from incomplete cases. It is usually
inefficient and may be biased when data are not MCAR [Ibrahim et al., 2012].
Imputation is also a common ad-hoc method for analysis of missing data. In general,
the imputation methods are conducted as following: at first we identify missing values from
the data, then we obtain a predictive model for the distribution of missing values given
observed data. Values are drawn from the predictive distribution. After imputations, the
usual estimation can be performed on the imputed dataset
{(x1, y1), (x2, y2), . . . , (xr, yr), (x1, y˜r+1), (x2, y˜r+2), ..., (xr, y˜n)}.
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where y˜′js are the imputed values. Imputation is a straightforward and flexible method.
However, appropriate imputation methods usually require a reasonable (estimated) impu-
tation model. The subsequent inference has to take into account of the variations due to
imputation models and the intrinsic variation due to the draws[Little and Rubin, 2002].
Multiple imputation are used to justify variation to improve single imputation. In mul-
tiple imputation, we repeatedly generate D (usually 2 ≤ D ≤ 10) complete data sets, then
we can achieve inference on θ by combining the estimations from D data sets[Rubin, 1987]
as follows:
θ¯D =
1
D
D∑
d=1
θˆd
(θ − θ¯D)T−
1
2
D ∼ tν
where TD is the variance of θ¯D computed from within-imputation variance and between im-
putation variance, ν is the degrees of freedom of the t distribution computed from D and
the variances.
The advantage of multiple imputation is the computation efficiency. Compared with
re-sampling methods such as bootstrap and jackknife, multiple imputation required fewer
times of repeating computation to obtain variance estimates of imputation estimates.
In summary, ad-hoc methods usually require data missing completely at random (M-
CAR) or missing at random (MAR), which limited the usage of such methods.
A generalized estimating equation (GEE) is used to estimate the parameters of a gener-
alized linear model with a possible unknown correlation between outcomes[Liang and Zeger,
1986]. The inference on θ could be done by solving the follow equation:
n∑
i=1
Di(xi, θ){yi − µ(xi, θ)} = 0
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where Di(x), θ is a d×K matrix chosen according to the distribution of yi, d is the dimension
of parameter θ, µ(x, θ) = E[Y |x].
Rubin and others presented the GEE method for the data missing at random (MAR)
using inverse probability weight (IPW) [Robins et al., 1994]. When we consider the missing
in data, the GEE based on the complete cases is:
r∑
i=1
Di(xi, θ){yi − g(xi, θ)} = 0
where the first r yi’s are observed. Supposed there is a fully observed auxiliary variable Z.
Assuming data are MAR
pr(Ri = 1|xi, yi, zi) = pr(Ri = 1|xi, zi;ψ) = f(xi, zi;ψ)
Using inverse-probability weight [Fitzmaurice et al., 1995], the inference on θ can be achieved
by solving the weighted GEE:
r∑
i=1
f(xi, zi; ψˆ)
−1Di(xi, θ){yi − g(xi, θ)} = 0
where ψˆ is usually estimated by regression of R on X and Z.
GEE is a well-established method, flexible for correlation structure adjustment. [Troxel
et al., 1997] extended GEE method for analysis of data with non-ignorable nonresponse.
However in general GEE methods are limited to data MAR or MCAR and the missing-data
mechanism is required in the likelihood function.
Likelihood-based methods can be classified into selection models and pattern-mixture
models by the way of likelihood partition. Selection models [Diggle and Kenward, 1994]
factor the joint distribution into underlying complete data distribution and missing data
mechanism:
p(Y,R; θ, ψ) = p(Y ; θ)p(R|Y ;ψ)
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Pattern mixture model [Little, 1994] stratify the data based on missing-data pattern:
p(Y,R; θ, ψ) = p(Y |R; θ)p(R;ψ)
Selection model is a natural way of factoring the model considering that the relationships
between Y and X in the full population is usually of interest. Also it will be shown later in
this section that when data are MAR, modeling missing-data mechanism is not necessary
for likelihood-based inference for selection models.
Pattern-mixture models, on the other hand, can be more suitable if the subpopulation
distribution is of interest. Also in some special situations, when data are NMAR, pattern
mixture models could be more convenient to perform than selection model.
Rubin showed that when data are missing at random (MAR) and missing-data mecha-
nism is distinct from the regression model, the missing-data mechanism can be ignored in
the likelihood-based inference [Rubin, 1976]:
Lfull(θ, φ;Yobs, R) =
∫
f(Yobs, Ymis; θ)f(R|Yobs, Ymis, ;φ)dYmis
=
∫
f(Yobs, Ymis; θ)f(R|Yobs;φ)dYmis
= f(Yobs; θ)f(R|Yobs;φ)
= Lign(θ)f(R|Yobs;φ)
where Lign(θ) = f(Yobs; θ) is the ignorable likelihood function. For data MAR, since the
second term in full likelihood becomes irrelevant to θ, inference based on Lfull(θ, φ;Yobs, R)
is equivalent to inference based on Lign(θ), and the missing-data mechanism does not need
to be modeled here.
When the MAR condition is not met, missing-data mechanism is required in construct-
ing full likelihood function for estimation and inference of regression parameters. Mis-
specification of missing-data model often yields biased estimates and wrong conclusions.
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In practice, it is often the case that we can not identify the missing-data mechanism.
Therefore, when applying likelihood based method for data missing not at random (NMAR),
people usually make some assumptions about the missing-data model. This is the motiva-
tion of the article to develop a general (missing-data mechanism assumption free) method
for regression analysis when missing-data mechanism is unknown.
Tanner and Wong showed that the posterior distribution of regression parameter given
observed data can be achieved by an iterative data augmentation procedure [Tanner and
Wong, 1987]. In the imputation step (I-step), the missing values are drawn from the dis-
tribution of missing values given observed values and given regression parameters In the
posterior step (P-step), the distribution of regression parameters are updated by the pos-
terior distribution of model parameters derived from the imputed dataset. This method is
called data augmentation.
For example, when data are MAR, Bayesian inference is based on the posterior distribu-
tion
p(θ|Yobs) ∝ p(θ)f(Yobs; θ)
where p(θ) is the prior distribution. A random sample are drawn from the posterior distribu-
tion of θ and its sample property can be used to make inference on θ. However, the posterior
distribution p(θ|Yobs) could be complicated. By data augmentation we iteratively simulates
random samples of missing values and models parameter given observed data, with 2 steps
in each iteration:
I Step (imputation): draw Y
(t+1)
mis with density p(Ymis|Yobs, θ(t+1));
P Step (posterior): Draw θ
(t+1)
mis with density p(θ|Yobs, Y (t+1)mis ) as if data were complete.
The iterations start with initial draw θ(0) from an approximation to the posterior distri-
bution of θ. As t → ∞, the iterative procedure will eventually yield a draw from the joint
distribution of p(θ|Yobs). Data augmentation methods are usually computationally intensive.
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Here we focus on maximum likelihood method, for the interest of dealing with more
general missing-data mechanisms. In the following context we will develop a modified EM
algorithm for regression analysis of data with non-responses when missing-data mechanism
unknown.
3.2 EM ALGORITHM FOR REGRESSION ANALYSIS OF DATA WITH
NON-RESPONSES WHEN THE MISSING-DATA MECHANISM IS
MODELED
Assume observed data Dobs,i = (xi, Riyi, Ri) for subject i = 1, 2, . . . , n. Suppose x′is be the
fully observed covariate; yi’s be partially observed responses, observed for i=1,2,. . . ,m; Ri’s
be the missing data indicator where Ri = 1 stand for observed yi and Ri = 1 for missing yi.
Without loss of generality, we assume for the complete data, the conditional distribution
with parameter θ follows an exponential family and canonical link.
yi|xi ∼ g(yi|xi; θ) ∝ exp{θS(xi, yi) + h(xi, yi) + a(θ)} (3.1)
Consider the following missing-data model
pr[Ri = 1|xi, yi] = w(xi, yi;ψ)
The interest is the inference of the distribution parameters θ.
When the parameters of the missing-data mechanism is distinct from the parameters of
the regression model, the likelihood function for (θ, ψ) given observed data follows
L(θ, ψ;Dobs) =
n∏
i=1
p(Ri, Riyi|xi; θ, ψ)
=
m∏
i=1
g(yi|xi; θ)w(xi, yi;ψ) ·
n∏
i=m+1
∫
g(yi|xi; θ){1− w(xi, yi;ψ)}dyi
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The likelihood function could also be written as
L(θ, ψ;Dobs) =
n∏
i=1
p(Ri, Riyi, (1−Ri)yi|xi; θ, ψ)
p((1−Ri)yi|Ri, Riyi, xi; θ, ψ)
=
n∏
i=1
p(Ri, yi|xi; θ, ψ)
p((1−Ri)yi|Ri, Riyi, xi; θ, ψ)
=
n∏
i=1
g(yi|xi; θ)p(Ri|xi, yi;ψ)
p((1−Ri)yi|Ri, Riyi, xi; θ, ψ)
The corresponding log-likelihood function is
l(θ, ψ;Dobs)
=
n∑
i=1
{log g(yi|xi; θ) + log p(Ri|xi, yi;ψ)− log p((1−Ri)yi|Ri, Riyi, xi; θ, ψ)} (3.2)
The MLE is
(θˆ, ψˆ) = arg max
θ,ψ
l(θ, ψ;Dobs)
The expectation-maximization (EM) algorithm is an iterative algorithm that is often used
to find the maximum likelihood estimate [Dempster et al., 1977]. Little and Rubin showed
that [Little and Rubin, 2002]
l(θ, ψ|Dobs) = l(θ, ψ|D)− ln f(Dmis|Dobs, θ, ψ)
where Dmis is the missing data and D= (Dobs,Dmis) is the hypothetical complete data . The
expectation of log-likelihood function given a current estimate of θ, say θ˜, is
l(θ, ψ|Dobs) = E[l(θ, ψ|D)|θ˜, ψ˜]− E[ln f(Dmis|Dobs, θ, ψ)|θ˜, ψ˜] (3.3)
Denote Q(θ, ψ|θ˜, ψ˜) = E[l(θ, ψ|D)|θ˜, ψ˜] and H(θ, ψ|θ˜, ψ˜) = E[ln f(Dmis|Dobs, θ, ψ)|θ˜, ψ˜],
which yields l(θ, ψ|Dobs) = Q(θ, ψ|θ˜, ψ˜)−H(θ, ψ|θ˜, ψ˜).
Each iteration of the EM algorithm include an E-step and an M-step. In the E-step,
given the current estimate (θ(t), ψ(t)), we need to calculate
Q(θ, ψ|θ(t), ψ(t)) =
n∑
i=1
E[{log g(yi|xi; θ) + log p(Ri|xi, yi;ψ)}|Ri, Riyi, xi; θ(t), ψ(t)]
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In the M-step, we update the parameters by finding the maximizer of the Q-function
giving the current estimate of parameters
(θ(t+1), ψ(t+1)) = arg max
(θ,ψ)
Q(θ, ψ; θ(t), ψ(t))
By Jansen’s Inequality, we have
H(θ, ψ; θ(t), ψ(t)) ≤ H(θ(t), ψ(t); θ(t), ψ(t))
this yield that l(θ(t+1), ψ(t+1);Dobs) ≥ l(θ(t), ψ(t);Dobs). Or in another way, maximizing log-
likelihood l(θ, ψ|Dobs) with respect to (θ, ψ) is equivalent as maximizing Q(θ, ψ; θ(t), ψ(t))
with respect to (θ, ψ) iteratively. Therefore the EM algorithm ensures increasing of the log-
likelihood, and the estimate of parameters converges at the MLE.
EM algorithm is relatively slow in convergence. Sometimes in the M-step, we do not have
explicit form of solution even the underlying complete data are from exponential family. EM
algorithm is stable that the likelihood function is always increasing.
However, in such maximum-likelihood method, since (θ, ψ) have to be estimated/updated
together, misspecification of the missing data model could lead to biased estimate of θ, and
usually researchers do not have information on the missing-data mechanism. This is the
motivation of our modified EM algorithm.
3.3 A MODIFIED EM ALGORITHM FOR REGRESSION ANALYSIS OF
DATA WITH NON-RESPONSES
We propose the modified EM algorithm using the following reasoning: when data are miss-
ing not at random (NMAR), and w(x, y;ψ) is unknown, if we can update θ(t) without using
information on ψ, the method will be useful in practice by ignoring the missing-data mech-
anism.
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3.3.1 EM algorithm for regression analysis of data with non-responses when
missing-data mechanism is known
Consider when ψ = ψ0 is known, the MLE is θˆ = arg max l(θ, ψ0;Dobs), where
l(θ, ψ0;Dobs) =
n∑
i=1
{[log g(yi|xi; θ) + log p(Ri|xi, yi;ψ0)− log p((1−Ri)yi]|Ri, Riyi, xi; θ, ψ0)}
Given current estimate θ(t), the corresponding Q-function becomes
Q(θ; θ(t)) =
n∑
i=1
E[{log g(yi|xi; θ) + log p(Ri|xi, yi;ψ0)}|Ri, Riyi, xi; θ(t), ψ0]
∝
n∑
i=1
E[log g(yi|xi; θ)|Ri, Riyi, xi; θ(t), ψ0]
Here the second term of Q-function is ignored because it is not related to θ. In the M-step
θ(t+1) = arg max
θ
Q(θ; θ(t))
The computation of Q-function in E-step is also simplified to
Q(θ; θ(t)) ∝
m∑
i=1
log g(yi|xi; θ) +
n∑
i=m+1
∫
log g(yi|xi; θ)g(yi|xi; θ(t))(1− w(xi, yi;ψ0))dy
where the first m subjects are observed, and the first term in the expectation can be directly
computed from the data; the rest (n−m) subjects have missing responses, and the compu-
tation of the second term depends on the missing-data mechanism w(x, y;ψ0).
Without loss of generality, consider the exponential family with canonical link as in (3.1),
we have
Q(θ; θ(t)) ∝
m∑
i=1
log g(yi|xi; θ) +
n∑
i=m+1
∫
log g(yi|xi; θ)g(yi|xi; θ(t))(1− w(xi, yi;ψ0))dy
∝
m∑
i=1
log g(yi|xi; θ) +
n∑
i=m+1
∫
{θS(xi, yi) + a(θ)}g(yi|xi; θ(t))(1− w(xi, yi;ψ0))dy
∝
m∑
i=1
log g(yi|xi; θ) + θ
m∑
i=1
E[S(xi, yi)|xi, Ri = 0, θ(t), ψ0] + (n−m)a(θ)
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Calculating Q(θ; θ(t)) is equivalent as updating E[S(xi, yi)|xi, Ri = 0, θ(t), ψ0]:
E[S(xi, yi)|xi, Ri = 0, θ˜, ψ0] =
∫
S(xi, yi)w(xi, y, ψ0)g(y|xi; θ˜)dy
pr[Ri = 0|xi, θ˜, ψ0]
Therefore, with known missing-data mechanism, we can updating the Q-function by it-
eratively applying the EM algorithm till convergence of θ.
3.3.2 An modified EM algorithm
For updating E[S(xi, yi)|xi, Ri = 0, θ(t), ψ0], alternatively we have
E[S(xi, yi)|xi, θ(t), ψ0] = E[S(xi, yi)|xi, Ri = 1, θ(t), ψ0] · pr[Ri = 1|xi, θ(t), ψ0]
+ E[S(xi, yi)|xi, Ri = 0, θ(t), ψ0] · pr[Ri = 0|xi, θ(t), ψ0]
Then we have
E[S(xi, yi)|xi, Ri = 0, θ(t), ψ0]
=
E[S(xi, yi)|xi, θ(t), ψ0]− E[S(xi, yi)|xi, Ri = 1, θ(t), ψ0] · pr[Ri = 1|xi, θ(t), ψ0]
pr[Ri = 0|xi, θ(t), ψ0] (3.4)
where E[S(xi, yi)|xi, Ri = 1, θ(t), ψ0], pr[Ri = 1|xi, θ(t), ψ0] and pr[Ri = 0|xi, θ(t), ψ0] are
calculated as:
E[S(xi, yi)|xi, Ri = 1, θ(t), ψ0] =
∫
S(xi, yi)w(xi, y, ψ0)g(y|xi; θ(t))dy
pr[Ri = 1|xi, θ(t), ψ0]
pr[Ri = 1|xi, θ(t), ψ0] =
∫
w(xi, y, ψ0)g(y|xi; θ(t))dy
pr[Ri = 0|xi, θ(t), ψ0] = 1− pr[Ri = 1|xi, θ(t), ψ0]
To compute the expectation of sufficient statistics giving missing, missing-data mecha-
nism is required. However, alternatively the terms E[S(xi, yi)|xi, Ri = 1, θ(t), ψ0], pr[Ri =
1|xi, θ(t), ψ0] and pr[Ri = 0|xi, θ(t), ψ0] in (3.4) can be replaced with empirical estimates
Eˆ[S(xi, yi)|xi, Ri = 1], pˆr[Ri = 1|xi], and pˆr[Ri = 0|xi] via nonparametric regression meth-
ods using the observed data (xi, yiRi, Ri). The missing-data mechanism w(xi, y, ψ0) is not
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required in such nonparametric smoothing process. The expectation of sufficient statistics
in the missing pattern can be approximated as following:
Eˆ[S(xi, yi)|xi, Ri = 0, θ(t)] = E[S(xi, yi)|xi, θ
(t)]− Eˆ[S(xi, yi)|xi, Ri = 1] · pˆr[Ri = 1|xi]
pˆr[Ri = 0|xi]
(3.5)
After the expectation of sufficient statistics given θ is obtained, the approximated Q-
function becomes
Q(θ; θ˜) ∝
m∑
i=1
log g(yi|xi; θ) +
n∑
i=m+1
E[log g(yi|xi; θ)|xi, Ri = 0; θ˜, ψ0]
∝
m∑
i=1
log g(yi|xi; θ) +
n∑
i=m+1
{θEˆ[S(xi, yi)|xi, Ri = 0; θ˜] + a(θ)} (3.6)
In order to obtain valid approximation in (3.6), θ˜ has to be a consistent estimate of θ,
such that empirical estimates in (3.5) be consistent with the original terms. Therefore, a
reasonable initial value of θ is very important for starting the proposed modified EM algo-
rithm. In general, we would need an external dataset without missing values for estimate
the parameters for the start of EM algorithm in the main data, and this is the trade-off of
the empirical estimation replacement.
In practice, we can obtain the initial value from an external data set with no missing
values, or from the recall results of a random subset of original sample Dobs. For simplicity,
all these complete small set are named as external set E for subsequent context.
Therefore, we have the proposed modified EM algorithm outlined as follows:
I. The preparation of the modified EM algorithm.
(i) We obtain empirical estimates of E[S(xi, yi)|xi, Ri = 1] and pr[Ri = 1|xi] via
nonparametric smoothing methods using the observed data (xi, yiRi, Ri).
(ii) We obtain an estimate of θ via an external data set with no missing values, and
use it as the initial value θ(0) to start the EM algorithm.
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II. In the E-step of the tth iteration, given the current estimate θ(t), we update the Q-
function as in (3.5) and (3.6) using empirical estimates of E[S(xi, yi)|xi, Ri = 1] and
pr[Ri = 1|xi] from the preparation step.
III. In the M-step, we update the values of the parameters as θ(t+1) by maximizing Q(θ; θ(t))
with respect to θ.
IV. We repeat the E-step and the M-step iteratively till convergence of θ.
The variance of estimates θˆ from the modified EM algorithm is not directly accessible
because the full likelihood function does not have explicit form and the observed information
matrix can not be computed. Therefore, in implementation, we use bootstrap re-sampling
method to compute an empirical variance for the estimates from modified EM algorithm.
3.3.3 Implementation of proposed methods in simple linear regression
As an example, consider simple linear regression as
yi = β0 + β1xi +N(0, σ
2) (3.7)
when there are no missing values, the MLE of θ = (β0, β1, σ
2) can be calculated as
βˆ1 =
∑n
i=1(xi−x¯)yi∑n
i=1(xi−x¯)2
βˆ0 = y¯ − βˆ1x¯
σˆ2 = 1
n
∑n
i=1(yi − βˆ0 − βˆ1xi)2
(3.8)
where x¯ =
∑n
i=1 xi and y¯ =
∑n
i=1 yi. Let the sufficient statistics from complete-data be
SS = (S1, S2, S3), where
S1 =
n∑
i=1
yi
S2 =
n∑
i=1
xiyi
S3 =
n∑
i=1
y2i
49
Suppose the responses Y ’s have missing values (observed for i = 1, . . . ,m) and covariate
X’s fully observed. In E-step of the (t + 1)th iteration of the modified EM algorithm, We
compute E[Sk|X, Yobs; θ(t)], k = 1, 2, 3, expectation of sufficient statistics given observed data
and current parameter estimates θ(t).
S
(t)
1 = E[S1|Dobs; θ(t)]
= E[
n∑
i=1
yi|Dobs; θ(t)]
=
m∑
i=1
yi + E[
n∑
i=m+1
yi|xi, Ri = 0, θ(t)]
=
m∑
i=1
yi +
n∑
i=m+1
β
(t)
0 + β
(t)
1 xi − Eˆ[y|xi, R = 1]pˆr(R = 1|xi)
pˆr(R = 0|xi)
In the above formula, Eˆ[y|xi, R = 1] and pˆr(R = 1|xi) are empirical estimates from observed
data via non-parametric regression.
Similarly, we have
S
(t)
2 = E[S2|Dobs; θ(t)]
= E[
n∑
i=1
xiyi|Dobs; θ(t)]
=
m∑
i=1
xiyi + E[
n∑
i=m+1
xiyi|xi, Ri = 0, θ(t)]
=
m∑
i=1
xiyi +
n∑
i=m+1
xi{β
(t)
0 + β
(t)
1 xi − Eˆ[y|xi, R = 1]pˆr(R = 1|xi)
pˆr(R = 0|xi) }
and
S
(t)
3 = E[S3|Dobs; θ(t)]
= E[
n∑
i=1
y2i |Dobs; θ(t)]
=
m∑
i=1
y2i + E[
n∑
i=m+1
y2i |xi, Ri = 0, θ(t)]
=
m∑
i=1
y2i +
n∑
i=m+1
(β
(t)
0 + β
(t)
1 xi)
2 + σ2
(t) − Eˆ[y2|xi, R = 1]pˆr(R = 1|xi)
pˆr(R = 0|xi)
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In the M-step, by replacing the data part in (3.8) with the updated expectation of
sufficient statistics, we have θ updated as
β
(t+1)
1 =
S
(t)
2 − x¯S(t)1∑n
i=1(xi − x¯)2
=
S
(t)
2 − ( 1n
∑n
i=1 xi)S
(t)
1∑n
i=1 x
2
i − 1n(
∑n
i=1 xi)
2
(3.9)
β
(t+1)
0 =
1
n
S
(t)
1 − β(t+1)1 x¯ =
1
n
S
(t)
1 − β(t+1)1
1
n
n∑
i=1
xi (3.10)
σ2
(t+1)
=
1
n
{S(t)3 −
1
n
(S
(t)
1 )
2 − β(t+1)1
2
n∑
i=1
(xi − x¯)2}
=
1
n
{S(t)3 −
1
n
(S
(t)
1 )
2 − β(t+1)1
2
[
n∑
i=1
x2i −
1
n
(
n∑
i=1
xi)
2]} (3.11)
3.3.4 Improvement of modified EM algorithm by involving external data
Let Ei = (xi, yi), i = n + 1, . . . , n + n∗ be the external data. In this complete external data
E with sample size n∗, (x, y) are all observed. Adding the information of E into the former
log-likelihood (3.2) gives the new log-likelihood:
l(θ, ψ0;Dobs,E ) =
n∑
i=1
{[log g(yi|xi; θ) + log p(Ri|xi, yi;ψ0)
− log p((1−Ri)yi]|Ri, Riyi, xi; θ, ψ0)}+
n+n∗∑
i=n+1
log g(yi|xi; θ)
and compared with (3.6), the new Q-function is
Q(θ; θ˜) ∝
m∑
i=1
log g(yi|xi; θ) +
n+n∗∑
i=n+1
log g(yi|xi; θ) +
n∑
i=m+1
E[log p(yi|xi; θ)|xi, Ri = 0; θ˜, ψ0]
∝
m∑
i=1
log g(yi|xi; θ) +
n+n∗∑
i=n+1
log g(yi|xi; θ) +
n∑
i=m+1
{θEˆ[S(xi, yi)|xi, Ri = 0; θ˜] + a(θ)}
The replacement of expectation of sufficient statistics terms with empirical estimate re-
mains the same as shown before. When the external complete data E with sample size n∗
are added in the log-likelihood function, we benefit more in the efficiency of the estimates
from the modified EM algorithm.
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3.3.5 The modified EM algorithm under discrete covariates
When X ′s are discrete, calculation of the empirical estimate terms in (3.6) can be simplified
as computing the mean in the group with the same given value of X. For example, when
xi ∈ (1, 2, . . . , L)
Eˆ[S(xi, yi)|xi = l, Ri = 1, θ(t)] =
∑m
j=1 S(l, yj; θ
(t)) · I{xj = l}∑m
j=1 I{xj = l}
pˆr[Ri = 1|xi = l] =
∑n
j=1Rj · I{xj = l}∑n
j=1 I{xj = l}
pˆr[Ri = 0|xi = l] = 1− pˆr[Ri = 1|xi = l]
3.3.6 Smoothing methods and its implementation in the modified EM algorithm
When X’s are continuous, the calculation of the empirical estimates Eˆ[y|xi, R = 1] and
pˆr(R = 1|xi) requires smoothing methods.
Given a sample(X1, Y1), . . . , (Xn, Yn),where Xi, Yi ∈ R, non-parametric regression or s-
moothing is concerned with estimating the regression function m(x) = E(Y |X = x), pre-
dicting Y given X from joint distribution of X and Y. We can write
Y = m(X) + 
A one-dimentional smoothing Kernel is any smooth function K such that K(x) ≥ 0 and∫
K(x) = 1,
∫
xK(x) = 0 and σ2K ≡
∫
x2K(x) > 0
Let h > 0 be bandwidth. Localized Square Error is defined by
n∑
i=1
K(
x−Xi
h
)(mˆ(x)− Yi)2
By minimizing Localized Square Error, we have The Nadaraya-Watson kernel estimator
mˆh(x) =
∑n
i=1 YiK(
x−Xi
h
)∑n
i=1 K(
x−Xi
h
)
=
n∑
i=1
Yili(x)
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where li(x) =
K(
x−Xi
h
)∑n
i=1K(
x−Xi
h
)
. Thus mˆh(x) is a local average of Yi’s. Here is the functional form
of Epanechnikov kernel
K(u) =
3
4
(1− u2)I|u|≤1
Gaussian kernel
K(u) =
1√
2pi
e−
1
2
u2
Box kernel
K(u) =
1
2
I|u|≤1
As described in section 3.3.2, in E-step of the proposed modified EM algorithm for regression
analysis of data with non-ignorable non-responses, we need to replace E[S(xi, y)|xi, Ri =
1, θ˜, ψ0], pr[Ri = 1|xi, θ˜, ψ0] and pr[Ri = 0|xi, θ˜, ψ0] with empirical estimates
Eˆ[S(xi, yi)|xi, Ri = 1], pˆr[Ri = 1|xi] and pˆr[Ri = 0|xi]. With the Nadaraya-Watson kernel
estimator we have
Eˆ[S(xi, yi)|xi, Ri = 1, θ˜] = mˆ1 h(xi) =
∑m
j=1 S(Xj, Yj)K(
xi−Xj
h
)∑m
j=1K(
xi−Xj
h
)
=
m∑
j=1
S(Xj, Yj)lj(xi)
pˆr[Ri = 1|xi] = mˆ2 h(xi) =
∑n
j=1 RjK(
xi−Xj
h
)∑n
j=1 K(
xi−Xj
h
)
=
n∑
j=1
Rjlj(xi)
Bandwidth selection is important in kernel regression. To simplify, we use fixed bandwidth
h = 0.1 after normalizing the data.
We use R function (ksmooth)1 for the nonparametric regression in calculating the em-
pirical estimates Eˆ[S(xi, yi)|xi, Ri = 1] and pˆr[Ri = 1|xi]. To improve the computing perfor-
mance of subroutines, we also develop our own R packages using C language for N-W kernel
smoothing with Epanechnikov, Gaussian and box kernel. The subroutines of modified EM
algorithms are written in R language.
1http://stat.ethz.ch/R-manual/R-patched/library/stats/html/ksmooth.html
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3.4 SIMULATION STUDIES
3.4.1 Simulation setup
In each simulation, data Dobs = (xi, Riyi), i = 1, . . . , n and E = (xi, yi), i = n+ 1, . . . , n+ n∗
are generated following a simple linear function as in (3.7). The regression parameters are
θ = (β0, β1, σ
2). Covariate xi’s are fully observed and response yi’s are observed for i =
1, . . . ,m. The missing-data indicator Ri’s are generated following a missing data mechanism
as
pr(Ri = 1|xi, yi;ψ) = Φ(ψ0 + ψ1xi + ψ2yi) (3.12)
where ψ = (ψ0, ψ1, ψ2) are the missing-data mechanism parameters.
In each simulation, we generate an external data with complete records and sample size
n∗ = 200 and another dataset with the response y is subject to missing values with sample
size n = 1000. Covariate X was either generated from X ∼ N(0, 1) or X ∼ BIN(5, 0.3) for
the consideration of continuous X and discrete X. Response Y s were generated following
(3.7) with θ = (1, 1, 1). When Xs are discrete, missingness of response Y s were generated fol-
lowing (3.12) with ψ = (−0.3, 0, 0) for MCAR, ψ = (−3.6, 2, 0) for MAR and ψ = (−6.3, 2, 1)
for NMAR. When Xs are continuous, missingness of response Y s were generated following
(3.12) ψ = (−0.3, 0, 0) for MCAR, ψ = (−0.7, 2, 0) for MAR and ψ = (−2, 2, 1) for NMAR.
The response missing rates are around 38% for all scenarios.
Plots of simulated data are shown in Figure 14. The red points are data with missing
responses Y , and black points are complete cases. Green lines are the underlying true linear
functions, and blue lines are fitted regression line using complete cases only. We can tell that
for data with responses missing not at random, the estimates could be severely biased, while
for data with response missing completely at random or missing at random, the estimates
are very close to the true regression line in the plots.
The following methods were considered for estimation of regression parameters in the
simulation study: the MLE from the analysis of the external data E , complete-case analysis
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(a) Y is MCAR & X ∼ BIN(5, 0.3) (b) Y is MAR & X ∼ BIN(5, 0.3)
(c) Y is NMAR & X ∼ BIN(5, 0.3) (d) Y is MCAR & X ∼ N(0, 1)
(e) Y is MAR & X ∼ N(0, 1) (f) Y is NMAR & X ∼ N(0, 1)
Figure 14: Plots of simulated data (x,y) in different scenarios.
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based on E and Dobs, the MLE from the analysis of the underlying complete data (CD), the
proposed modified EM algorithm using Dobs and E (proposed methods). In Modified EM
algorithm using Dobs and E method, when X is continuous, we used box kernel, Gaussian
kernel and Epanechnikov kernel in empirical estimation of the expectation of sufficient s-
tatistics given missing.
Simulations were repeated for K=1000 times. For each simulated dataset, each method
will be applied in estimating parameters. he empirical bias and empirical standard deviation
of estimates from the above-mentioned methods were computed and compared. Bootstrap
re-sampling for the estimation of regression parameters was performed for B=200 times in
each simulation, and the 95%CI coverage from each methods are computed and compared.
3.4.2 Simulation results
Table 5 summarizes the performance of these methods on inference of distribution parameter
θ = (β0, β1, σ
2) for regression of simulated data with discrete predictor X and response Y
MCAR, MAR and NMAR. Predictor X’s were generated following a binomial distribution
X ∼ BIN(5, 0.3).
Table 6 summarizes the methods’ performance on inference of distribution parameter
θ = (β0, β1, σ
2) for regression of simulated data with continuous predictor X and response
Y missing completely at random (MCAR), missing at random (MAR) and missing not at
random (NMAR). Predictor X’s were generated following a normal distribution X ∼ N(0, 1).
From Table 5 and Table 6, when response Y is missing completely at random (MCAR) or
missing at random (MAR), the results suggest that the modified EM algorithm (except for
Gaussian kernel when predictor X is continuous) yielded negligible bias, which is similar to
the MLE from the external data set and the MLE using complete cases from the combined
data set. The 95% Bootstrap confidence intervals from the modified EM algorithm (except
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Table 5: Simulation results when the predictor X ∼ BIN(5, 0.3)
Emp. Bias Emp. SDa 95%CI Coverageb
Mechanism Method β0 β1 σ
2 β0 β1 σ
2 β0 β1 σ
2
MCAR MLE for E -12 25 -111 1245 688 976 94.7% 94.2% 94.3%
CC Analysis -26 14 -46 618 341 490 94.6% 94.4% 94.3%
CD MLE -20 8 -34 526 297 404 94.1% 93.5% 94.8%
Modified EM -9 23 -107 1237 677 975 94.3% 95.0% 92.9%
MAR MLE for E -12 25 -111 1245 688 976 94.7% 94.2% 94.3%
CC Analysis -32 27 -37 571 431 491 95.1% 94.8% 94.8%
CD MLE -20 8 -34 526 297 404 94.1% 93.5% 94.8%
Modified EM -17 27 -54 671 495 635 94.6% 94.2% 93.5%
NMAR MLE for E -12 25 -111 1245 688 976 94.7% 94.2% 94.3%
CC Analysis 156 -1412 -354 574 446 477 94.1% 10.4% 88.4%
CD MLE -20 8 -34 526 297 404 94.1% 93.5% 94.8%
Modified EM -16 27 -50 662 492 731 94.7% 93.9% 93.6%
aAll values in the table ×10, 000
bAsymptotic CI used for MLE using external data, complete-case analysis, and MLE using underlying
complete data; Bootstrap re-sampling for B = 200 times used for modified EM.
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Table 6: Simulation results when the predictor X ∼ N(0, 1)
Emp. Bias Emp. SDa 95%CI Coverageb
Mechanism Methodc β0 β1 σ
2 β0 β1 σ
2 β0 β1 σ
2
MCAR MLE for E -26 9 -103 693 743 991 95.7% 93.6% 95.2%
Complete cases -7 7 -26 350 350 494 94.0% 94.4% 95.4%
CD MLE -5 10 -15 289 289 408 95.0% 94.8% 96.0%
MEM-Box -22 28 -135 764 659 1052 97.2% 94.5% 95.7%
MEM-Gaussian -25 231 -381 650 577 897 95.1% 92.0% 89.5%
MEM-Epan. -23 48 -148 643 561 890 95.6% 93.2% 92.3%
MAR MLE for E -26 9 -103 693 743 991 95.7% 93.6% 95.2%
Complete cases -12 1 -24 386 411 488 94.2% 95.6% 93.6%
CD MLE -5 10 -15 289 289 408 95.0% 94.8% 96.0%
MEM-Box -0.1 -1 -63 596 481 678 95.0% 94.8% 95.6%
MEM-Gaussian 113 831 -151 558 476 640 93.5% 94.6% 92.8%
MEM-Epan. 11 11 -73 556 472 641 93.9% 94.5% 93.7%
NMAR MLE for E -26 9 -103 693 743 991 95.7% 93.6% 95.2%
Complete cases -2009 -1388 -486 380 422 468 0.0% 7.6% 81.4%
CD MLE -5 10 -15 289 289 408 95.0% 94.8% 96.0%
MEM-Box -69 2 -156 592 484 652 95.9% 95.2% 93.4%
MEM-Gaussian 25 73 -248 552 476 624 94.0% 94.8% 91.1%
MEM-Epan. -97 -11 -161 551 472 624 95.0% 95.2% 93.4%
aAll values in the table ×10, 000.
bAsymptotic CI used for MLE using external data, complete-case analysis, and MLE using underlying
complete data; Bootstrap re-sampling for B = 200 times used for modified EM.
cMEM kernel smoothing bandwidth is set fixed at 0.1.
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for Gaussian kernel when predictor X is continuous) had nominal coverage of the true values
of regression parameters. The estimates from modified EM algorithm were more efficient
than the ones from the external data but less efficient than the MLE using complete cases
from the combined data set.
When response Y is NMAR, the modified EM algorithm yielded negligible bias, which is
similar to the MLE from the external data set. The 95% Bootstrap confidence intervals from
the modified EM algorithm (except for Gaussian kernel when predictor X is continuous) had
nominal coverage of the true values of regression parameters. Based on MSE, our proposed
modified EM algorithm gives the best performance considering the consistency and efficiency.
3.5 ANALYSIS OF QUALIFY-OF-LIFE DATA FROM A CANCER
CLINICAL TRIAL
R-04 is a clinical trial conducted by NSABP2 comparing preoperative radiation therapy and
Capecitabine with or without Oxaliplatin with preoperative radiation therapy and contin-
uous intravenous infusion of 5-Fluorouracil with or without Oxaliplatin in the treatment of
patients with operable carcinoma of the rectum [Monga and O’Connell, 2006].
The quality-of-life score (QOL) in R-04 trial were measured for the patients before treat-
ment (baseline) and 1 year after treatment. We use QOL at baseline as predictor X and
QOL after treatment as response Y. There were no missingness in the data. The sample
size is 1266. For the purpose of illustration, 200 patients were selected as external com-
plete data set. In the rest, we artificially generated missing values in Y following (3.12)
where ψ = (−1.2, 2, 1). Therefore the responses are not missing at random (NMAR) and
the proportion of non-response was about 38%. Figure 15 shows the data with generated
missingness.
2The National Surgical Adjuvant Breast and Bowel Project. http://www.nsabp.pitt.edu
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Table 7 summarizes the performance of the MLE from the analysis of the external data E ,
Complete case analysis based on E and Dobs, and proposed modified EM algorithm method
on inference of distribution parameter θ = (β0, β1, σ
2) for regression analysis of quality of
life (QOL) data with continuous X (QOL at baseline) and responses Y (QOL measured 1
year after treatment) missing not at random (NMAR). The missing indicators are generated
following a NMAR mechanism. The response missing rate is 38.4%. The regression estimate
of θ from original data is θˆ = (0.00, 0.57, 0.68).
The data analysis results suggest that when response Y is NMAR and predictor X is
continuous, the modified EM algorithm yielded negligible bias, which is similar to the MLE
from the external data set; The 95% Bootstrap confidence intervals from the modified EM
algorithm covered the regression estimates from original data; The estimates from modified
EM algorithm are more efficient than the ones from the external data but less efficient
than the MLE using complete cases from the combined data set. However, the complete-
case analysis based on the combined data set is severely biased and the confidence intervals
did not cover the regression estimates from original data. The conclusions agree with our
simulation studies.
3.6 SUMMARY AND DISCUSSION
We proposed a modified EM algorithm in maximum likelihood approach for missing-data
analysis, when the modeling of the missing-data mechanism is not necessary.
Simulation studies and data analysis were performed to compare the proposed modified
EM algorithm method with the MLE using external data and complete case analysis.
The simulation studies suggest that the modified EM algorithm yields estimates with
negligible bias regardless of the nature of the missing-data mechanism. For data with dis-
60
Figure 15: NSABP R-04 Trial: QOL before treatment vs QOL after treatment.
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Table 7: Data analysis: patients’ QOL in R-04 trial.
Estimate Biasa 95% CI and widthb
Methodc Smoothingd β0 β1 σ
2 β0 β1 σ
2
MLE E -0.02 -0.02 0.05 (-0.14,0.09) (0.44,0.66) (0.56,0.89)
0.24 0.22 0.33
CC analysis -0.20 -0.15 -0.02 (-0.26,-0.14) (0.36,0.47) (0.58,0.74)
0.12 0.11 0.15
CD MLE 0.00 0.00 0.00 (-0.05,-0.05) (0.52,0.61) (0.61,0.74)
0.09 0.09 0.13
Modified EM Box -0.07 -0.06 -0.02 (-0.18,0.04) (0.43,0.59) (0.57,0.75)
0.22 0.16 0.17
Gaussian -0.05 -0.05 -0.02 (-0.15,0.05) (0.44,0.59) (0.57,0.75)
0.20 0.16 0.18
Epan. -0.07 -0.06 -0.01 (-0.17,0.02) (0.43,0.58) (0.58,0.75)
0.19 0.15 0.17
aregression estimates from original data: θ = (0.00, 0.57, 0.68)
bAsymptotic CI’s used for external data MLE, complete-case analysis and MLE using underlying
complete data; Bootstrap for B=200 times used for modified EM methods
cSample size 1266, external data n∗ = 200, incomplete data n = 1066, response missing rate 38.4%.
dMEM kernel smoothing bandwidth is set fixed bw = 0.1.
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crete covariate X, the empirical bias of estimates is always smaller than 0.015, the empirical
bias/ empirical standard deviation ratio is always smaller than 1
9
. For data with continuous
covariate X, the empirical bias of estimates from modified EM method is slightly larger
because of non-parametric regression boundary issue, but still less than 0.02 for Box and
Epanechnikov kernel. The empirical bias/SD ratio is less than or around 1
4
for Box and
Epanechnikov kernel.
Second, the method does not require specification or modeling of the missing-data mech-
anism. This is the most important advantage of the proposed algorithm. The simulation
results showed that no matter the data is MCAR, MAR or NMAR, the bias were mostly
negligible and the coverage of the 95% CI were around the nominal level. Complete case
analysis is biased when data are NMAR.
The estimates derived from the modified EM algorithm are more efficient than the MLE
from the external complete data. Modified EM algorithm always have similar bias as the
MLE from external data, and estimates from modified EM algorithm achieved an empirical
SD (about 30%) smaller than the asymptotic SE of MLE using external data when data are
MAR and MNAR.
In case where predictor X is discrete, the proposed modified EM algorithm outperform
the MLE using external complete data, because the empirical estimate terms can be simpli-
fied as marginal means. When predictor X is continuous, the performance of the proposed
methods is related with the kernel choice and bandwidth selection. From simulation results,
Box and Epanechnikov kernel are appropriate choices for this algorithm.
In future research , we plan to improve the modified EM algorithm in magnitude of bias
and efficiency when predictor X is continuous by the improving the approximation of the Q-
function. We plan to work on bandwidth selection in the smoothing process and improving
the estimation at boundary.
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